Anti-PEG Antibodies

Detect PEGylated molecules with monoclonal anti-PEG antibodies — validated for ELISA, WB, and immunoassay. Essential for PEGylated drug PK studies. RUO

Pourquoi les chercheurs choisissent abinScience

Réactifs hautement spécialisés Purpose-built antibodies for niche research applications with validated performance data on every datasheet.

Validation rigoureuse des applications Each antibody tested in relevant applications with supporting images and quantitative data.

Fabricant d'origine Developed and produced in-house — full traceability, batch consistency, and competitive pricing.

Support technique expert Application scientists available for reagent selection, protocol optimization, and troubleshooting.

Options flexibles Unconjugated and conjugated formats; bulk quantities and custom conjugation available on request.

Documents & données QC

Download product datasheets, images de validation (WB/IHC/IF/FC), CoA, and application protocols on each product page. All data is lot-specific.

FAQ

Comment vos anticorps sont-ils validés ?

Every antibody is validated in its listed applications (WB, IHC, IF, ELISA, FC) with supporting images and data on the product page. We use positive and negative controls plus knockout/knockdown verification where available.

Proposez-vous des anticorps conjugués ?

Yes — HRP, AP, biotin, FITC, PE, APC, Alexa Fluor, and other fluorochrome conjugates are available. Custom conjugation services are also offered for bulk orders.

Avec quelles espèces vos anticorps réagissent-ils ?

Most antibodies target human, mouse, and rat. Many show validated cross-reactivity with additional species. Check the product datasheet for confirmed reactivity data.

Quelle est votre politique de remplacement ?

If a product does not perform as described under recommended conditions, contact us within 30 days for replacement or credit. Our technical team will help troubleshoot first.

Puis-je obtenir des anticorps personnalisés ?

Yes — our parent company AtaGenix offers full custom antibody development from immunogen design through hybridoma screening and scale-up production.